Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Epigenetic Regulation

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...

Epigenetic Regulation

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

Mismatch Repair

Mismatch Repair

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Instruments for Measuring Healthcare Professionals' Medication Safety Competence: A Scoping Review.

Journal of multidisciplinary healthcare·2025

Same author

A bell-shaped dependence between amyloidosis and GABA accumulation in astrocytes in a mouse model of Alzheimer's disease.

Neurobiology of aging·2017

Same author

Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.

The Journal of clinical investigation·2017

Same author

In vivo odourant response properties of migrating adult-born neurons in the mouse olfactory bulb.

Nature communications·2015

Same author

High-resolution in vivo imaging of microglia using a versatile nongenetically encoded marker.

European journal of immunology·2012

Same author

Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.

The Journal of clinical investigation·2012

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Dot Blot Assay for Detecting Global N6-Methyladenosine RNA Modification Levels

Dot Blot Assay for Detecting Global N⁶-Methyladenosine RNA Modification Levels

Published on: February 6, 2026

Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression

Marina Hermes¹, Hermann Geisler, Hartmut Osswald

¹Department of Pharmacology and Toxicology, Faculty of Medicine, University of Tübingen, Wilhelmstrasse 56, D-72074 Tübingen, Germany.

Biochemical Pharmacology

|April 9, 2008

Summary

Elevating S-adenosylhomocysteine (AdoHcy) levels inhibits O(6)-methylguanine DNA methyltransferase (MGMT) mRNA expression, suggesting a new strategy to enhance cancer therapy effectiveness against alkylating agents.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter

Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter

Published on: May 29, 2019

Related Experiment Videos

Last Updated: Jul 6, 2026

Dot Blot Assay for Detecting Global N6-Methyladenosine RNA Modification Levels

Dot Blot Assay for Detecting Global N⁶-Methyladenosine RNA Modification Levels

Published on: February 6, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter

Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter

Published on: May 29, 2019

Area of Science:

Biochemistry
Molecular Biology
Cancer Research

Background:

O(6)-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme crucial for cellular defense against alkylating agents.
MGMT's role in cancer therapy involves modulating its expression, often lost due to MGMT promoter hypermethylation.
Intracellular S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy) levels influence DNA and mRNA methylation, potentially regulating MGMT expression.

Purpose of the Study:

To investigate the role of the AdoMet/AdoHcy ratio in regulating MGMT promoter methylation and mRNA expression.
To explore the potential of modulating AdoHcy levels as a therapeutic strategy in cancer treatment.

Main Methods:

Analysis of AdoMet/AdoHcy ratios and MGMT promoter methylation patterns in glioblastoma and hepatoma cell lines.
Experimental manipulation of AdoMet/AdoHcy ratios using an AdoHcy hydrolase inhibitor (adenosine-2',3'-dialdehyde).
Assessment of global DNA methylation, MGMT promoter methylation, and MGMT mRNA levels under varying AdoHcy conditions.

Main Results:

AdoMet/AdoHcy ratios varied widely across cell lines, but were not correlated with MGMT promoter methylation or global DNA methylation under control conditions.
Experimental elevation of AdoHcy levels, achieved by inhibiting AdoHcy hydrolase, did not alter global or MGMT promoter methylation.
Elevated AdoHcy significantly decreased MGMT mRNA levels by over 50% in MGMT-expressing cell lines, likely due to impaired mRNA methylation.

Conclusions:

The AdoMet/AdoHcy ratio does not appear to regulate MGMT promoter methylation.
Elevating AdoHcy levels pharmacologically, via AdoHcy hydrolase inhibition, is a potential strategy to reduce MGMT mRNA expression.
This approach could enhance cancer cell sensitivity to alkylating agents, improving therapeutic outcomes.